Which hedge funds own ASND? ASCENDIS PHARMA A/S, Q2 2026 13F holders
10 of the hedge funds tracked by WhaleCreep disclosed a position in ASND (ASCENDIS PHARMA A/S) in their Q2 2026 13F filings, worth $2.9bn in total. The largest holder by portfolio weight is RA Capital Management at 23.7% of its book. 10 managers opened a new position this quarter: RA Capital Management, Woodline Partners, Millennium Management, Renaissance Technologies LLC. 9 exited: Ancora Advisors, Brevan Howard Capital Management, D. E. Shaw & Co.
10tracked managers holding
10opened this quarter
9exited this quarter
Which hedge funds hold ASND? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| RA Capital Management | Q2 2026 | 23.7% | $2.7bn | 10,281,496 | – | new |
| Woodline Partners | Q2 2026 | 0.1% | $27.3m | 102,469 | – | new |
| Millennium Management | Q2 2026 | 0.0% | $71.1m | 266,708 | – | new |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $31.9m | 119,699 | – | new |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $2.1m | 7,930 | – | new |
| Citadel Advisors | Q2 2026 | 0.0% | $36.8m | 137,889 | – | new |
| Tudor Investment | Q2 2026 | 0.0% | $4.4m | 16,625 | – | new |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $8.2m | 30,883 | – | new |
| Marshall Wace | Q2 2026 | 0.0% | $6.0m | 22,503 | – | new |
| Ancora Advisors | Q2 2026 | 0.0% | $3.2k | 12 | – | new |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Ancora Advisors | 0.0% | $2.7k |
| Brevan Howard Capital Management | 0.5% | $6.0m |
| D. E. Shaw & Co | 0.0% | $242.9k |
| Millennium Management | 0.5% | $43.2m |
| Point72 Asset Management LP | 1.6% | $70.5m |
| Polen Capital Management | 0.4% | $414.5k |
| RA Capital Management | 75.0% | $2.4bn |
| Renaissance Technologies LLC | 0.5% | $26.8m |
| Woodline Partners | 0.9% | $23.4m |
How has hedge fund ownership of ASND changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 10 | $2.9bn |
| Q1 2026 | 9 | $2.5bn |
| Q4 2025 | 7 | $2.3bn |
| Q3 2025 | 7 | $2.1bn |
| Q2 2025 | 6 | $1.9bn |
| Q1 2025 | 7 | $1.8bn |
| Q4 2024 | 6 | $1.6bn |
| Q3 2024 | 9 | $1.6bn |
| Q2 2024 | 6 | $1.4bn |
| Q1 2024 | 6 | $1.6bn |
| Q4 2023 | 4 | $1.3bn |
| Q3 2023 | 4 | $1.0bn |
| Q2 2023 | 4 | $1.0bn |
| Q1 2023 | 4 | $869.2m |
| Q4 2022 | 6 | $928.0m |
| Q3 2022 | 5 | $851.0m |
Counts every tracked manager that disclosed ASND in that quarter's filing, including managers that have since stopped filing.